The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

MLA

Böhmer, Gabriele M., et al. “The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions.” Journal of Clinical Pharmacology, vol. 49, no. 4, Apr. 2009, pp. 389–97. EBSCOhost, https://doi.org/10.1177/0091270008330980.

APA

Böhmer, G. M., Nassr, N., Wenger, M., Hünnemeyer, A., Lahu, G., Templin, S., Gleiter, C. H., & Hermann, R. (2009). The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. Journal of Clinical Pharmacology, 49(4), 389–397. https://doi.org/10.1177/0091270008330980

Chicago

Böhmer, Gabriele M, Nassr Nassr, Marcus Wenger, Andreas Hünnemeyer, Gezim Lahu, Silke Templin, Christoph H Gleiter, and Robert Hermann. 2009. “The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions.” Journal of Clinical Pharmacology 49 (4): 389–97. doi:10.1177/0091270008330980.